BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration
agreement with Eisai Inc., which will enable Eisai to use Cerveau’s
[F-18]MK-6240, an investigational imaging agent, in Positron Emission
Tomography (PET) scans to assess the status and progression of
neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated
tau protein are a hallmark of several neurodegenerative diseases,
including Alzheimer’s disease.
The collaboration is focused on using [F-18]MK-6240 as a biomarker in
Eisai neurodegenerative disease research studies. The companies will
collaborate to evaluate the effect of investigational therapeutics on
the potential treatment of neurodegenerative diseases in humans.
“Cerveau is focused on enhancing access to key technologies that we
believe have the potential to advance human health,” said Rick Hiatt,
chief executive officer, Cerveau Technologies, Inc. “We are excited to
welcome Eisai to our growing network of pharmaceutical partners and
global production sites. Our goal is to expand the availability of this
novel investigational imaging agent to the broader scientific community.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical
Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is
globally develop diagnostics and technology that positively impact
patients with neurodegenerative disorders including Alzheimer’s disease.
About Eisai Inc.
Eisai Inc. is a fully integrated pharmaceutical business with discovery,
clinical, manufacturing and marketing capabilities. Our key areas of
focus include oncology and neurology (dementia-related diseases and
neurodegenerative diseases). To learn more about Eisai Inc., please
visit us at Eisai.com/us.
Contacts
Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com